Course Description
Discover the evolving landscape of psychotropic medications and how new advancements are reshaping mental health treatment. This presentation will delve into zuranolone (Liz Taber), buprenorphine (David Dadiomov), and suzetrigine (Emily Leppien), highlighting their unique benefits and limitations. Gain practical insights into integrating these innovative therapies into clinical practice, potentially enhancing patient outcomes and expanding your treatment toolkit as a psychiatric pharmacist.
This session will focus on clinical experience and practical application of each medication rather than reviewing the underlying scientific evidence behind them.
Learning Objectives
- Identify the clinical advantages and/or disadvantages of newer psychotropic medications.
- Discuss practical application and where newer psychotropic medications fit into clinical practice.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Liz Taber, PharmD, BCPP
Clinical Pharmacy Specialist, UNC Health
Chapel Hill, NC
Liz Taber, PharmD, BCPP, is a board-certified Clinical Pharmacy Specialist in Psychiatry at UNC Health and the Program Director of the PGY2 Psychiatric Pharmacy Residency Program. She earned her Doctor of Pharmacy degree from the Nesbitt School of Pharmacy at Wilkes University, followed by a PGY1 Pharmacy Residency at CJW Medical Center in Richmond, Virginia, and a PGY2 Psychiatric Pharmacy Residency at UNC Health. Prior to returning to UNC Health in 2021, Dr. Taber held clinical positions at St. Luke’s University Health Network and the North Carolina Department of Health and Human Services’ Central Regional Hospital. She also serves as an Adjunct Assistant Professor at the UNC Eshelman School of Pharmacy.
Outside of work, Liz enjoys running, hiking, baking, reading, and crafting. She especially loves spending time with her husband and young son as well as hosting friends and family.
David Dadiomov, PharmD, BCPP
Associate Professor of Clinical Pharmacy, University of Southern California; Clinical Psychiatric Pharmacist, Addiction Medicine, Los Angeles General Medical Center
Los Angeles, CA
David Dadiomov, PharmD, BCPP, is an Associate Professor of Clinical Pharmacy at the University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and Director of the PGY2 Psychiatric Pharmacy Residency Program. A board-certified psychiatric pharmacist, he specializes in addiction medicine and the care of patients with complex psychiatric and substance use disorders.
At Los Angeles General Medical Center, Dr. Dadiomov provides inpatient psychiatric and addiction consultations, delivers care through street medicine services, and manages a pharmacist-led outpatient addiction clinic. In partnership with Los Angeles County Health Services, he has developed clinical pharmacy services that extend treatment to people experiencing homelessness, individuals involved in the criminal legal system, and those with complex medical needs.
Dr. Dadiomov has authored peer-reviewed journal articles and book chapters on addiction treatment, harm reduction, and emerging psychiatric therapies, and co-edited the textbook Ketamine: Fundamentals, Applications, Delivery Systems and Clinical Aspects. His scholarship includes national consensus recommendations addressing barriers to buprenorphine access and grant-supported initiatives integrating clinical pharmacy services into safety-net care. Across his clinical practice, research, and teaching, his work advances the role of psychiatric pharmacists in translating emerging evidence into accessible treatment for underserved populations.
Emily E. Leppien, PharmD, BCPS, BCPP
Clinical Associate Professor, Department of Pharmacy Practice
Binghamton University School of Pharmacy Pharmaceutical Sciences
Binghamton, NY
Emily Leppien, PharmD, BCPS, BCPP, is a Clinical Associate Professor at Binghamton University School of Pharmacy and Pharmaceutical Sciences. She provides didactic and experiential education in psychiatry, neurology, pain management, and substance use disorders. As part of her faculty appointment, Dr. Leppien established a clinical practice at Guthrie Binghamton Pain Care, where she provides comprehensive pain management and behavioral health services. Within this practice, she integrates the treatment of mental health conditions and substance use disorders into chronic pain care. Dr. Leppien's professional and research interests focus on non-opioid strategies for chronic pain management, pain management in patients with opioid use disorder (OUD), integration of behavioral health services into chronic pain care, and the safe and appropriate use of psychotropic medications. In addition to her service with the American Association of Psychiatric Pharmacists (AAPP), Dr. Leppien is actively involved in the American Pharmacists Association (APhA) and the Society of Pain and Palliative Care Pharmacists (SPPCP).
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 4/7/2027-4/7/2030
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-##-###-###-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.